Fig. 1: Identification of the stromal and epithelial GR target gene signature after GC treatment. | Oncogene

Fig. 1: Identification of the stromal and epithelial GR target gene signature after GC treatment.

From: Targeting the glucocorticoid receptor signature gene Mono Amine Oxidase-A enhances the efficacy of chemo- and anti-androgen therapy in advanced prostate cancer

Fig. 1

A Heat map of top 36 significantly up-regulated and top 20 significantly down-regulated genes of stromal PF179TCAF-shGR-1 cells. B Significantly altered GR target genes of PF179TCAF-shGR-1 cells, after control DMSO treatment as well as after 100 nM Dex, 100 nM Dex + 1 µg/ml Dox, and 100 nM Dex and 12 µM RU486 treatment for 24 h. C Heat map of top 36 significantly up-regulated and top 20 significantly down-regulated genes of epithelial abl-Enza and abl-Abi cells. D Significantly altered GR target genes of abl-Enza and abl-Abi cells, after control DMSO treatment as well as after 100 nM Dex treatment for 24 h. E Identification of 27 mutual significantly up-regulated GR target genes between the LREX´ and abl-Enza/Abi datasets. F Identification of four mutual significantly up-regulated stromal and epithelial GR target genes within the CAF, abl-Enza/Abi and LREX´ datasets.

Back to article page